<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: Additional ", fill: "#ffef00"},
{source: "3: Additional ", target: "3: uncertainties", fill: "#ffef00"},
{source: "3: uncertainties", target: "3: presently known", fill: "#ffef00"},
{source: "3: presently known", target: "3: otherwise may also impair", fill: "#ffef00"},
{source: "3: otherwise may also impair", target: "3: operations", fill: "#ffef00"},
{source: "3: operations", target: "3: common stock", fill: "#ffef00"},
{source: "3: Additional ", target: "4: risks described", fill: "#986960"},
{source: "4: risks described", target: "4: risks actually", fill: "#986960"},
{source: "4: risks actually", target: "4: financial condition", fill: "#986960"},
{source: "4: financial condition", target: "4: operations could", fill: "#986960"},
{source: "4: operations could", target: "4: materially", fill: "#986960"},
{source: "4: materially", target: "4: adversely affected", fill: "#986960"},
{source: "4: risks described", target: "10: future profitability will depend", fill: "#e6e8fa"},
{source: "10: future profitability will depend", target: "10: on several factors", fill: "#e6e8fa"},
{source: "10: on several factors", target: "10: appropriately priced", fill: "#e6e8fa"},
{source: "10: appropriately priced", target: "10: profitable businesses", fill: "#e6e8fa"},
{source: "10: profitable businesses", target: "10: provide cash flow", fill: "#e6e8fa"},
{source: "10: provide cash flow", target: "10: will provide", fill: "#e6e8fa"},
{source: "10: will provide", target: "10: flow from operations which will fund growth", fill: "#e6e8fa"},
{source: "10: flow from operations which will fund growth", target: "10: service debt", fill: "#e6e8fa"},
{source: "10: service debt", target: "10: access reasonably priced capital", fill: "#e6e8fa"},
{source: "10: access reasonably priced capital", target: "10: longterm flexibility", fill: "#e6e8fa"},
{source: "10: future profitability will depend", target: "13: financial services", fill: "#adff2f"},
{source: "13: financial services", target: "13: profitable existing businesses", fill: "#adff2f"},
{source: "13: profitable existing businesses", target: "13: cash flows", fill: "#adff2f"},
{source: "13: financial services", target: "15: At December ", fill: "#c00"},
{source: "15: At December ", target: "15: approximately", fill: "#c00"},
{source: "15: approximately", target: "15: cash equivalents", fill: "#c00"},
{source: "15: At December ", target: "21: independent auditors", fill: "#39ff14"},
{source: "21: independent auditors", target: "21: financial statements", fill: "#39ff14"},
{source: "21: financial statements", target: "21: December ", fill: "#39ff14"},
{source: "21: December ", target: "21: would continue as", fill: "#39ff14"},
{source: "21: independent auditors", target: "36: management team", fill: "#fcc200"},
{source: "36: management team", target: "36: significant", fill: "#fcc200"},
{source: "36: significant", target: "36: history upon which", fill: "#fcc200"},
{source: "36: history upon which", target: "36: easily evaluate", fill: "#fcc200"},
{source: "36: easily evaluate", target: "36: future potential", fill: "#fcc200"},
{source: "36: management team", target: "44: businesses with unknown", fill: "#ff69b4"},
{source: "44: businesses with unknown", target: "44: contingent", fill: "#ff69b4"},
{source: "44: contingent", target: "44: liabilities", fill: "#ff69b4"},
{source: "44: liabilities", target: "44: comply with healthcare", fill: "#ff69b4"},
{source: "44: comply with healthcare", target: "44: regulations", fill: "#ff69b4"},
{source: "44: businesses with unknown", target: "45: conduct detailed due", fill: "#ecd540"},
{source: "45: conduct detailed due", target: "45: diligence reviews", fill: "#ecd540"},
{source: "45: diligence reviews", target: "45: potential acquisition candidates", fill: "#ecd540"},
{source: "45: potential acquisition candidates", target: "45: compliance with", fill: "#ecd540"},
{source: "45: compliance with", target: "45: healthcare laws", fill: "#ecd540"},
{source: "45: healthcare laws", target: "45: businesses", fill: "#ecd540"},
{source: "45: businesses", target: "45: applicable laws but there", fill: "#ecd540"},
{source: "45: applicable laws but there", target: "45: procedures will", fill: "#ecd540"},
{source: "45: procedures will", target: "45: potential problems", fill: "#ecd540"},
{source: "45: conduct detailed due", target: "56: profitability", fill: "#f4a460"},
{source: "56: profitability", target: "56: negatively", fill: "#f4a460"},
{source: "56: negatively", target: "56: impacted by", fill: "#f4a460"},
{source: "56: impacted by", target: "56: relationships with", fill: "#f4a460"},
{source: "56: relationships with", target: "56: largest institutional", fill: "#f4a460"},
{source: "56: profitability", target: "67: regulations at both", fill: "#ffae42"},
{source: "67: regulations at both", target: "67: federal levels", fill: "#ffae42"},
{source: "67: federal levels", target: "67: reimbursement", fill: "#ffae42"},
{source: "67: reimbursement", target: "67: pharmacy services", fill: "#ffae42"},
{source: "67: pharmacy services", target: "67: relationships", fill: "#ffae42"},
{source: "67: relationships", target: "67: manufacturers", fill: "#ffae42"},
{source: "67: manufacturers", target: "67: pharmaceuticals", fill: "#ffae42"},
{source: "67: pharmaceuticals", target: "67: certification", fill: "#ffae42"},
{source: "67: certification", target: "67: operations", fill: "#ffae42"},
{source: "67: operations", target: "67: regulations may", fill: "#ffae42"},
{source: "67: regulations may", target: "67: profitability as", fill: "#ffae42"},
{source: "67: profitability as", target: "67: fully described", fill: "#ffae42"},
{source: "67: regulations at both", target: "80: pharmacy reimbursement methodology will", fill: "#c46210"},
{source: "80: pharmacy reimbursement methodology will", target: "80: average sales price", fill: "#c46210"},
{source: "80: average sales price", target: "80: competitive acquisition", fill: "#c46210"},
{source: "80: competitive acquisition", target: "80: payment methodology", fill: "#c46210"},
{source: "80: payment methodology", target: "80: profitability", fill: "#c46210"},
{source: "80: pharmacy reimbursement methodology will", target: "82: Currently ", fill: "#e5b73b"},
{source: "82: Currently ", target: "82: contracts with major facility customers use", fill: "#e5b73b"},
{source: "82: contracts with major facility customers use", target: "82: methodologies as", fill: "#e5b73b"},
{source: "82: methodologies as", target: "82: calculating", fill: "#e5b73b"},
{source: "82: calculating", target: "82: prices charged", fill: "#e5b73b"},
{source: "82: prices charged", target: "82: drugs ordered through", fill: "#e5b73b"},
{source: "82: Currently ", target: "84: client institutions fail", fill: "#9b111e"},
{source: "84: client institutions fail", target: "84: comply with", fill: "#9b111e"},
{source: "84: comply with", target: "84: Medicaid and Medicare ", fill: "#9b111e"},
{source: "84: Medicaid and Medicare ", target: "84: reimbursement regulations", fill: "#9b111e"},
{source: "84: reimbursement regulations", target: "84: revenue could", fill: "#9b111e"},
{source: "84: revenue could", target: "84: could lose", fill: "#9b111e"},
{source: "84: could lose", target: "84: eligibility", fill: "#9b111e"},
{source: "84: eligibility", target: "84: participate", fill: "#9b111e"},
{source: "84: client institutions fail", target: "142: removed from listing on", fill: "#905d5d"},
{source: "142: removed from listing on", target: "142: Nasdaq Market ", fill: "#905d5d"},
{source: "142: Nasdaq Market ", target: "142: additional", fill: "#905d5d"},
{source: "142: additional", target: "142: requirements", fill: "#905d5d"},
{source: "142: requirements", target: "142: brokerdealers", fill: "#905d5d"},
{source: "142: brokerdealers", target: "142: institutional", fill: "#905d5d"},
{source: "142: institutional", target: "142: accredited", fill: "#905d5d"},
{source: "142: removed from listing on", target: "START_HERE", fill: "#905d5d"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Diversified Financial Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_Profitability_Analysis">Customer Profitability Analysis</a></td>
      <td>Customer Profitability Analysis (in short CPA) is a management accounting and a credit underwriting method, allowing businesses and lenders to determine the profitability of each customer or segments of customers, by attributing profits and costs to each customer separately. CPA can be applied at the individual customer level (more time consuming, but providing a better understanding of business situation) or at the level of customer aggregates / groups (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porter's_five_forces_analysis">Porter's five forces analysis</a></td>
      <td>Porter's Five Forces Framework is a method of analysing the operating environment of a competition of a business. It draws from industrial organization (IO) economics to derive five forces that determine the competitive intensity and, therefore, the attractiveness (or lack thereof) of an industry in terms of its profitability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_31">December 31</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vyera_Pharmaceuticals">Vyera Pharmaceuticals</a></td>
      <td>Vyera Pharmaceuticals (formerly Turing Pharmaceuticals) is a pharmaceutical company incorporated in Zug, Switzerland, with offices in New York City. The company started to do business in the US as Vyera Pharmaceuticals in September 2017.The company has two marketed products: Daraprim (pyrimethamine), for the treatment of toxoplasmosis, and Vecamyl (mecamylamine hydrochloride) for the treatment of hypertension.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Capitation_(healthcare)">Capitation (healthcare)</a></td>
      <td>Capitation is a payment arrangement for health care service providers. It pays a set amount for each enrolled person assigned to them, per period of time, whether or not that person seeks care.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitable_growth">Profitable growth</a></td>
      <td>Profitable Growth is the combination of profitability and growth, more precisely the combination of Economic Profitability and Growth of Free cash flows. Profitable growth is aimed at seducing the financial community; it emerged in the early 80s when shareholder value creation became firms’ main objective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/SAP_ERP">SAP ERP</a></td>
      <td>SAP ERP is an enterprise resource planning software developed by the German company SAP SE. SAP ERP incorporates the key business functions of an organization. The latest version of SAP ERP (V.6.0) was made available in 2006.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reimbursement">Reimbursement</a></td>
      <td>Reimbursement is the act of compensating someone for an out-of-pocket expense by giving them an amount of money equal to what was spent.Companies, governments and nonprofit organizations may compensate their employees or officers for necessary and reasonable expenses; under US\nlaw, these expenses may be deducted from taxes by the organization and treated as untaxed income for the recipient provided that accountability conditions are met. UK law provides for deductions for travel and subsistence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_mileage_reimbursement_rate">Business mileage reimbursement rate</a></td>
      <td>The business mileage reimbursement rate is an optional standard mileage rate used in the United States for purposes of computing the allowable business deduction, for Federal income tax purposes under the Internal Revenue Code, at 26 U.S.C. § 162, for the business use of a vehicle. Under the law, the taxpayer for each year is generally entitled to deduct either the actual expense amount, or an amount computed using the standard mileage rate, whichever is greater.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_reimbursement_account">Health reimbursement account</a></td>
      <td>A Health Reimbursement Account, formally a Health Reimbursement Arrangement (HRA), is a type of US employer-funded health benefit plan that reimburses employees for out-of-pocket medical expenses and, in limited cases, to pay for health insurance plan premiums.An HRA is not truly an account, since it does not place funds under a separate legal title. Instead, it is an agreement under which the employee can submit qualified health expenses to the employer for reimbursement.Following implementation of the Affordable Care Act, HRAs must be integrated with a qualified employer-sponsored group health insurance plan to avoid excise tax penalties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Teva_Pharmaceuticals">Teva Pharmaceuticals</a></td>
      <td>Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Alembic_Pharmaceuticals">Alembic Pharmaceuticals</a></td>
      <td>Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price">Price</a></td>
      <td>A prince is a male ruler (ranked below a king, grand prince, and grand duke) or a male member of a monarch's or former monarch's family. Prince is also a title of nobility (often highest), often hereditary, in some European states.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price_discrimination">Price discrimination</a></td>
      <td>Price discrimination is a microeconomic pricing strategy where identical or largely similar goods or services are sold at different prices by the same provider in different markets. Price discrimination is distinguished from product differentiation by the more substantial difference in production cost for the differently priced products involved in the latter strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pricing">Pricing</a></td>
      <td>Pricing is the process whereby a business sets the price at which it will sell its products and services, and may be part of the business's marketing plan. In setting prices, the business will take into account the price at which it could acquire the goods, the manufacturing cost, the marketplace, competition, market condition, brand, and quality of product.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Comply_or_Die">Comply or Die</a></td>
      <td>Comply or Die (1999–2016) was a British-trained Thoroughbred racehorse, owned by David Johnson.  Ridden by Timmy Murphy and trained by David Pipe he was the winner of the 2008 John Smith's Grand National at Aintree Racecourse, run on Saturday 5 April 2008.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Airworthiness_Directive">Airworthiness Directive</a></td>
      <td>An Airworthiness Directive (commonly abbreviated as AD) is a notification to owners and operators of certified aircraft that a known safety deficiency with a particular model of aircraft, engine, avionics or other system exists and must be corrected.If a certified aircraft has outstanding airworthiness directives that have not been complied with, the aircraft is not considered airworthy. Thus, it is mandatory for an aircraft operator to comply with an AD.\n\n\n== Purpose ==\nADs usually result from service difficulty reporting by operators or from the results of aircraft accident investigations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/CBS_Dream_Team">CBS Dream Team</a></td>
      <td>CBS Dream Team (suffixed with ...It's Epic! before October 3, 2020) is an American programming block that is programmed by Hearst Media Production Group (formerly Litton Entertainment), and airs weekend mornings on CBS under a time-lease agreement as a replacement for the WildBrain-produced animation block Cookie Jar TV. The block features six half-hour live-action documentary and lifestyle series aimed at teenagers between the ages of 13 and 16, which are designed to comply with educational programming requirements defined by the Federal Communications Commission (FCC) under the Children's Television Act.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Craig_Finn">Craig Finn</a></td>
      <td>Craig Finn (born August 22, 1971) is an American singer-songwriter and musician. He is best known as the frontman of the American indie rock band The Hold Steady, with whom he has recorded eight studio albums.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/National_Information_Infrastructure_Protection_Act">National Information Infrastructure Protection Act</a></td>
      <td>The National Information Infrastructure Protection Act (Pub.L. 104–294 (text) (PDF), 110 Stat. 3488, enacted October 11, 1996; H.R. 3723) was Title II of the Economic Espionage Act of 1996, as an amendment to the Computer Fraud and Abuse Act.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Montana_State_Auditor">Montana State Auditor</a></td>
      <td>The Montana State Auditor is a constitutional officer in the executive branch of government of the U.S. state of Montana. The State Auditor is elected once every four years, concurrent with the state's gubernatorial election and the U.S. presidential election.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>STANDARD MANAGEMENT CORP      Item 1A Risk Factors               In addition to the other information in this report and our other     <font color="blue">filings with</font> the U S Securities and Exchange Commission (“SEC”), the     following risk factors should be <font color="blue">carefully</font> considered in evaluating Standard     <font color="blue">Management </font>and our <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>The risks and <font color="blue"><font color="blue">uncertainties</font> described</font> below     are not the only ones we face</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font>, not     <font color="blue">presently known</font> to us or otherwise, may also impair our business <font color="blue">operations</font>     or the trading of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">risks described</font> below or     such  other <font color="blue">risks actually</font> occur, our business, <font color="blue">financial condition</font> or     results of <font color="blue">operations</font> could be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>- 7 -       _________________________________________________________________    [42]Table of <font color="blue">Contents       </font>Our pharmacy business has not <font color="blue">been profitable</font> and we expect it to continue     to <font color="blue">incur losses</font> for at least the next year</td>
    </tr>
    <tr>
      <td>Since we began operating our pharmacy business in 2002, it has     incurred substantial <font color="blue">net losses each year</font></td>
    </tr>
    <tr>
      <td>For the years 2005, 2004 and     2003,  net  losses  from our continuing <font color="blue">operations</font> were dlra20dtta3 million,     dlra20dtta6 million and dlra16dtta7 million, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We expect net losses to     <font color="blue">continue until</font> we <font color="blue">generate <font color="blue">significant</font> revenues</font> and achieve economies of     scale in our <font color="blue">operations</font> through <font color="blue"><font color="blue">acquisition</font>s</font> and <font color="blue">organic growth</font></td>
    </tr>
    <tr>
      <td>There can     be  no assurance that we will ever be able to <font color="blue">successfully</font> develop and     operate a <font color="blue">profitable pharmacy</font> business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future <font color="blue">profitability</font> will depend</font>     <font color="blue">on several factors</font> including:       •   our ability to identify and acquire <font color="blue">appropriately priced</font> and     profitable <font color="blue">businesses</font> that <font color="blue">provide cash flow</font> and synergies to our current     business;         •   our ability to execute a planned strategy that <font color="blue">will provide</font> for cash     flow from <font color="blue">operations</font> which will fund growth and <font color="blue">service debt</font>; and         •   our ability to <font color="blue">access reasonably priced capital</font> that <font color="blue">will provide</font>     long-term flexibility for the Company</td>
    </tr>
    <tr>
      <td>Unless we receive a <font color="blue"><font color="blue"><font color="blue">significant</font> cash</font> infusion</font> or <font color="blue"><font color="blue">significant</font>ly increase cash</font>     flow from <font color="blue">operations</font>, we may not have <font color="blue">sufficient cash</font> to meet our cash     <font color="blue"><font color="blue">requirement</font>s at</font> some point during 2006</td>
    </tr>
    <tr>
      <td>Our pharmacy business alone has not <font color="blue">generated sufficient revenues</font>     to support our <font color="blue">operations</font> and service our <font color="blue">debt obligations</font></td>
    </tr>
    <tr>
      <td>We implemented a     growth plan, subsequent to the sale of our <font color="blue">financial services</font> business in     June 2005, focused on acquiring profitable existing <font color="blue">businesses</font> to increase     our revenues and <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>The funding of this growth plan and our ability     to meet our working capital and other <font color="blue">cash <font color="blue">requirement</font>s</font> generally, depend     on, among other things, current cash and <font color="blue">cash equivalents</font> and <font color="blue">proceeds from</font>     <font color="blue"><font color="blue">outside financing</font> <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">At <font color="blue">December </font></font>31, 2005, we had <font color="blue">approximately</font>     dlra2dtta2 million in cash and <font color="blue">cash equivalents</font></td>
    </tr>
    <tr>
      <td>On April 13, 2006, we received     dlra2dtta8 million of <font color="blue">debt financing from one</font> of our officers</td>
    </tr>
    <tr>
      <td>Nevertheless, based     on  current  estimates  of cash flow, <font color="blue">management</font> believes that, absent     <font color="blue"><font color="blue">significant</font> <font color="blue">additional</font> cash infusion</font> or <font color="blue"><font color="blue">significant</font>ly increased cash flow</font>     from <font color="blue">operations</font>, at some point during 2006, we may not have <font color="blue">sufficient cash</font>     to meet our <font color="blue">cash <font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>is <font color="blue">currently negotiating</font> a series     of  <font color="blue"><font color="blue">transaction</font>s</font>  it  believes <font color="blue">would alleviate</font> the <font color="blue">potential liquidity</font>     shortfall</td>
    </tr>
    <tr>
      <td>There can be no assurance, however, that <font color="blue">outside financing</font>     <font color="blue">activities</font>  will  generate  sufficient  net proceeds or that the other     <font color="blue"><font color="blue">initiatives</font> currently</font> being <font color="blue">negotiated by <font color="blue">management</font></font> can be consummated in     full or <font color="blue">at sufficient levels</font> to provide us with <font color="blue">sufficient cash</font> to meet our     <font color="blue">cash <font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">independent auditors</font> have expressed substantial doubt regarding the     Company’s ability to <font color="blue">continue as</font> a going concern</td>
    </tr>
    <tr>
      <td>In  their  report,  our <font color="blue">independent auditors</font> stated that our     <font color="blue">financial statements</font> for the years ended <font color="blue">December </font>31, 2005 and 2004 were     prepared assuming that the Company would <font color="blue">continue as</font> a going concern</td>
    </tr>
    <tr>
      <td>The     auditors  expressed “substantial doubt” about the Company’s ability to     <font color="blue">continue as</font> a going concern <font color="blue">based on</font> a lack of <font color="blue">liquidity combined with</font>     recurring losses from continuing <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The fact that we have received     this “going concern opinion” from our <font color="blue">auditors will likely</font> make it more     <font color="blue">difficult</font> for us to <font color="blue">raise capital on</font> favorable terms and <font color="blue">could hinder</font>, to     some extent, our <font color="blue">operations</font> and <font color="blue"><font color="blue">acquisition</font> program</font></td>
    </tr>
    <tr>
      <td>We will require <font color="blue">additional</font> financing, which may be <font color="blue">difficult</font> to obtain</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">such financing</font> in the form of <font color="blue">debt will contain restrictive covenants</font> and     will require us to <font color="blue">utilize cash</font> to service it</td>
    </tr>
    <tr>
      <td>Our pharmacy business has had negative <font color="blue">cash flows</font> and net losses     since its inception in 2002</td>
    </tr>
    <tr>
      <td>We expect negative <font color="blue">cash flows</font> from <font color="blue">operations</font>     to <font color="blue">continue until</font> we achieve <font color="blue">critical mass through <font color="blue"><font color="blue">acquisition</font>s</font></font> and organic     growth</td>
    </tr>
    <tr>
      <td>Our business has <font color="blue"><font color="blue">significant</font> cash</font> needs for <font color="blue">operations</font> and for     <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>As a result, we will likely need to seek <font color="blue">additional</font> capital,     which we may do through public or private equity or debt financing</td>
    </tr>
    <tr>
      <td>In     addition to <font color="blue">seeking equity financing</font>, we are <font color="blue">currently negotiating</font> with     <font color="blue">various potential lenders</font> to <font color="blue">provide senior debt financing</font></td>
    </tr>
    <tr>
      <td>There can be no     assurance that we can <font color="blue">reach agreement with</font> any lenders for <font color="blue">such financing</font></td>
    </tr>
    <tr>
      <td>The terms of any <font color="blue">such debt financing</font>, will likely restrict our ability to,     among other things, incur <font color="blue">additional</font> indebtedness, pay dividends or make     certain other <font color="blue">restricted payments</font> in certain situations, consummate certain     asset sales, enter into certain <font color="blue"><font color="blue">transaction</font>s</font> with affiliates, incur liens,     or merge or <font color="blue">consolidate with</font> any other person or sell, assign, transfer,                                       - 8 -       _________________________________________________________________    [43]Table of <font color="blue">Contents       </font>lease,  convey or <font color="blue">otherwise dispose</font> of all or <font color="blue">substantially</font> all of our     assets</td>
    </tr>
    <tr>
      <td>The terms of <font color="blue">such indebtedness would <font color="blue">also likely</font></font> require us to meet     <font color="blue">certain financial tests</font> and <font color="blue"><font color="blue">comply with</font> certain</font> other reporting, <font color="blue">affirmative</font>     and  negative  covenants</td>
    </tr>
    <tr>
      <td>Finally, if we obtain <font color="blue">such debt financing</font>, a     substantial portion of our cash flow from <font color="blue">operations</font> would be dedicated to     <font color="blue">debt service <font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">management</font> team</font> has a limited history of operating a pharmacy business</td>
    </tr>
    <tr>
      <td>Because we have only operated our pharmacy business since 2002,     our <font color="blue"><font color="blue">management</font> team</font> does not have a <font color="blue">significant</font> operating <font color="blue">history upon which</font>     an investor can <font color="blue">easily evaluate</font> our <font color="blue">future potential</font></td>
    </tr>
    <tr>
      <td>In attempting to     execute  our  business  model, we may need to <font color="blue">significant</font>ly change our     operating model, sales and <font color="blue">implementation</font> practices, customer service and     support <font color="blue">operations</font> and <font color="blue"><font color="blue">management</font> focus</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">also facing new risks</font> and     <font color="blue">challenges</font>, including a lack of <font color="blue">meaningful historical financial data upon</font>     which  to  plan  future  budgets  and  the  need  to develop strategic     <font color="blue">relationships</font></td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">various risks</font> relating to our <font color="blue"><font color="blue">acquisition</font> strategy</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> component of our <font color="blue">growth strategy</font> contemplates our     making selected <font color="blue"><font color="blue">acquisition</font>s</font> that <font color="blue">will help expand</font> our <font color="blue">pharmacy offerings</font></td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font>involve inherent <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">uncertainties</font> include the     ability to identify <font color="blue">suitable <font color="blue">acquisition</font> candidates</font> and negotiate acceptable     terms  for  their  <font color="blue">acquisition</font>,  the ability to integrate the acquired     <font color="blue">businesses</font> into a <font color="blue">larger organization</font> and the <font color="blue">availability</font> of <font color="blue">management</font>     resources to oversee the <font color="blue">operations</font> of these <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>The successful     <font color="blue">integration</font> of acquired <font color="blue">businesses</font> will require, <font color="blue">among others</font>:       •   <font color="blue">consolidation</font> of <font color="blue">financial functions</font> and <font color="blue">elimination</font> of <font color="blue">redundancies</font>;         •   <font color="blue">achievement</font> of <font color="blue">purchasing efficiencies</font>;         •   the <font color="blue">integration</font> of <font color="blue">key personnel</font>; and         •   the maintenance and growth of existing business</td>
    </tr>
    <tr>
      <td>We  also  may  acquire <font color="blue">businesses</font> with unknown or <font color="blue">contingent</font>     <font color="blue">liabilities</font>, including <font color="blue">liabilities</font> for failure to <font color="blue"><font color="blue">comply with</font> healthcare</font>     laws and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We have procedures in place to <font color="blue">conduct detailed due</font>     <font color="blue">diligence reviews</font> of potential <font color="blue">acquisition</font> candidates for <font color="blue">compliance with</font>     <font color="blue">healthcare laws</font> and to conform the practices of acquired <font color="blue">businesses</font> to our     standards  and <font color="blue">applicable laws</font>, but there can be no assurance that our     <font color="blue">procedures will</font> detect all <font color="blue">potential problems</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">such procedures fail</font>, we     may incur material <font color="blue">liabilities</font> for past <font color="blue">activities</font> of acquired <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>We cannot be sure that an <font color="blue">acquisition</font> will not have an adverse     <font color="blue">impact on</font> our results of <font color="blue">operations</font> or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We  face <font color="blue">uncertainties</font> relating to <font color="blue">ongoing litigation</font> that, if decided     <font color="blue">adversely</font> to us, would have a material adverse <font color="blue">impact on</font> our liquidity and     <font color="blue">financial position</font></td>
    </tr>
    <tr>
      <td>We are currently engaged in <font color="blue">binding <font color="blue">arbitration</font> with</font> our former     President/Chief  Financial Officer</td>
    </tr>
    <tr>
      <td>This <font color="blue">former executive resigned</font> all     <font color="blue">positions with us <font color="blue">effective</font></font> May 31, 2005 and has <font color="blue">initiated legal proceedings</font>     to <font color="blue">recover certain severance amounts</font> to which he alleges he is entitled</td>
    </tr>
    <tr>
      <td>We believe that the     executive’s claims are <font color="blue">entirely without merit</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">vigorously defending</font>     this action</td>
    </tr>
    <tr>
      <td>While we are confident in the merits of our <font color="blue">legal position</font> in     the <font color="blue">arbitration</font>, we <font color="blue">cannot predict</font> the outcome of this <font color="blue">action nor</font> the amount     the <font color="blue"><font color="blue">arbitrators</font> will ultimately rule</font> is due to the executive, if anything</td>
    </tr>
    <tr>
      <td>A     <font color="blue">decision by</font> the <font color="blue">arbitrators</font> requiring us to pay a <font color="blue">significant</font> amount to the     <font color="blue">executive would</font> have a substantial negative <font color="blue">impact on</font> our liquidity and     <font color="blue">financial position</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">profitability</font> and ability to conduct business could be <font color="blue">negatively</font>     <font color="blue">impacted by</font> a change in our <font color="blue">relationships</font> with our <font color="blue">largest <font color="blue">institutional</font></font>     clients</td>
    </tr>
    <tr>
      <td>A  large  portion  of  the  present and <font color="blue">future growth</font> of our     <font color="blue"><font color="blue">institutional</font> pharmacy</font> business currently is <font color="blue">contingent</font> upon our ability to     acquire and retain <font color="blue"><font color="blue">institutional</font> care <font color="blue">facilities</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Currently </font>we have more     than  80  contractual <font color="blue">relationships</font> with <font color="blue"><font color="blue">institutional</font> clients</font></td>
    </tr>
    <tr>
      <td>We are     <font color="blue">presently attempting</font> to expand the number of these contracts</td>
    </tr>
    <tr>
      <td>The financial     condition and <font color="blue">profitability</font> of our <font color="blue"><font color="blue">institutional</font> clients</font> can impact our     <font color="blue">profitability</font> and <font color="blue">opportunities</font> for <font color="blue">future growth</font></td>
    </tr>
    <tr>
      <td>In addition, although we     believe our current <font color="blue">relationships</font> with our <font color="blue"><font color="blue">institutional</font> clients</font> are strong,     the loss of key <font color="blue"><font color="blue">institutional</font> clients</font> would <font color="blue">materially</font> affect the operation     of our business</td>
    </tr>
    <tr>
      <td>- 9 -       _________________________________________________________________    [44]Table of <font color="blue">Contents       </font>We <font color="blue">face intense competition</font></td>
    </tr>
    <tr>
      <td>We operate in a <font color="blue">highly competitive environment</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">institutional</font>     <font color="blue">pharmacy industry</font> is dominated by three companies, which together control     <font color="blue">approximately</font>  65prca of the market</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">compete with</font> our     <font color="blue">competition due</font> to our size, failure to develop <font color="blue">innovative <font color="blue">distribution</font></font>     methods or failure to satisfy our customers, our financial results will be     <font color="blue">immediately</font> and <font color="blue">significant</font>ly affected</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">significant</font> <font color="blue">government</font>al regulation, and changes in such     <font color="blue">regulation could</font> have a substantial <font color="blue">impact on</font> our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We are subject to substantial <font color="blue">regulations</font> at both the state and     <font color="blue">federal levels</font> regarding payment or <font color="blue">reimbursement</font> for <font color="blue">pharmacy services</font>,     financial   <font color="blue">relationships</font>   with  our  clients  and  <font color="blue">manufacturers</font>  of     <font color="blue"><font color="blue">pharmaceutical</font>s</font>, and licensure and <font color="blue">certification</font> of our <font color="blue">operations</font>, and     changes in these <font color="blue">regulations</font> may have a material and adverse effect on our     <font color="blue">profitability</font> as more <font color="blue">fully described</font> below</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on payment</font> or <font color="blue">reimbursement</font> from <font color="blue">government</font> <font color="blue">reimbursement</font>     programs, principally Medicare and Medicaid, and the constant changes in the     <font color="blue">government</font> <font color="blue">reimbursement</font> programs pose substantial risk to our results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The provision of <font color="blue"><font color="blue">pharmaceutical</font>s</font> and <font color="blue">pharmacy benefits</font> is a highly     dynamic and evolving business that is <font color="blue">tied closely</font> to changes in <font color="blue">government</font>     <font color="blue">reimbursement</font> programs at both the state and <font color="blue">federal levels</font> and is in a     constant state of flux</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, <font color="blue">approximately</font> 36prca of our     <font color="blue">pharmacy billings</font> were directly <font color="blue">reimbursed by</font> <font color="blue">government</font> <font color="blue">sponsored programs</font></td>
    </tr>
    <tr>
      <td><font color="blue">Government </font><font color="blue">sponsored programs</font> include Medicaid and, to a <font color="blue">lesser extent</font>,     Medicare</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">remaining billings</font> are <font color="blue">currently paid</font> or <font color="blue">reimbursed by</font>     individual  residents, long-term care <font color="blue">facilities</font> and other third-party     payors,  including  private  insurers</td>
    </tr>
    <tr>
      <td>A portion of these revenues are     indirectly dependent on <font color="blue">government</font> programs</td>
    </tr>
    <tr>
      <td>We anticipate that direct     <font color="blue">reimbursement</font> from <font color="blue">government</font> <font color="blue">sponsored programs</font> will become a material     portion of our <font color="blue">pharmacy billings</font></td>
    </tr>
    <tr>
      <td>There  are  currently  a  number of active state and federal     <font color="blue">initiatives</font> that could <font color="blue">materially</font> and <font color="blue">adversely</font> affect our <font color="blue">profitability</font>,     the <font color="blue">most important</font> of which is the Medicare Prescription Drug Improvement     and Modernization Act of 2004, which created a <font color="blue">comprehensive</font> voluntary     <font color="blue">prescription</font> drug benefit <font color="blue">administered</font> under <font color="blue">Medicare Part D </font>and became     <font color="blue">effective</font>  on  January 1, 2006</td>
    </tr>
    <tr>
      <td>This Act provides certain cost-sharing     <font color="blue">government</font> subsidies for <font color="blue">individuals</font> who <font color="blue">might otherwise qualify</font> for drug     <font color="blue">coverage under</font> Medicaid or similar <font color="blue">government</font>-funded aid programs</td>
    </tr>
    <tr>
      <td>Since a     substantial portion of our future <font color="blue"><font color="blue">institutional</font> pharmacy</font> business will     involve the provision of <font color="blue">prescription</font> drugs <font color="blue">to Medicare </font><font color="blue">beneficiaries</font> who     may qualify for this new benefit, it may have a material and adverse effect     on the <font color="blue">profitability</font> of our business</td>
    </tr>
    <tr>
      <td>Since <font color="blue">important elements</font> of this Act     relating to issues such as formulary development, drug pricing, and drug     discount  cards  have  yet  to  be  finalized,  the  <font color="blue">precise impact</font> of     <font color="blue">implementation</font> of <font color="blue">Medicare Part D </font>on our industry is unknown</td>
    </tr>
    <tr>
      <td>We  also  expect  <font color="blue">significant</font> reforms to be proposed in 2006     regarding the <font color="blue">Medicare Part B </font><font color="blue">drug <font color="blue">payment <font color="blue">methodology</font></font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue">United States </font>    Department of Health and Human Services, Centers for <font color="blue">Medicare and Medicaid </font>    Services has indicated that the pharmacy <font color="blue">reimbursement</font> <font color="blue">methodology</font> will     change  to either an “<font color="blue">average sales price</font>” or “competitive <font color="blue">acquisition</font>     program”  <font color="blue">payment <font color="blue">methodology</font></font>, and this change may have a material and     adverse effect on our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Many state Medicaid <font color="blue">programs use</font> the “<font color="blue">average wholesale price</font>”     <font color="blue">reimbursement</font>  <font color="blue">methodology</font>  (“AWP”)  and the “<font color="blue">maximum allowable costs</font>”     <font color="blue">reimbursement</font> <font color="blue">methodology</font> (“MAC”), but many states, including states in     which we operate or may operate, have indicated an intention to <font color="blue">discontinue</font>     or modify these <font color="blue">payment methodologies</font>, and such changes may have a material     and adverse effect on our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Currently, virtually all of our     <font color="blue">contracts with major facility customers use</font> these <font color="blue">methodologies as</font> a basis     for <font color="blue">calculating</font> the <font color="blue">prices charged</font> for <font color="blue">drugs ordered through</font> our pharmacy</td>
    </tr>
    <tr>
      <td>In the event state <font color="blue">reimbursement</font> programs decide to use <font color="blue">alternative</font> methods     for <font color="blue">calculating</font> these prices, our <font color="blue">reimbursement</font> may suffer</td>
    </tr>
    <tr>
      <td>If we or our <font color="blue"><font color="blue">client institutions</font> fail</font> to <font color="blue">comply with</font> <font color="blue">Medicaid and Medicare     </font><font color="blue">reimbursement</font> <font color="blue">regulations</font>, our <font color="blue">revenue could</font> be reduced, we could be subject     to penalties and we <font color="blue">could lose</font> our <font color="blue">eligibility</font> to <font color="blue">participate</font> in these     programs</td>
    </tr>
    <tr>
      <td><font color="blue">The Medicaid and Medicare </font>programs are <font color="blue">highly regulated</font></td>
    </tr>
    <tr>
      <td>The     failure, even if inadvertent, by either us or our <font color="blue">client institutions</font> to     <font color="blue">comply with</font> applicable <font color="blue">reimbursement</font> <font color="blue">regulations</font> could <font color="blue">adversely</font> affect     <font color="blue">reimbursement</font>  under these programs and our or our clients’ ability to     continue to <font color="blue">participate</font> in these programs</td>
    </tr>
    <tr>
      <td>In addition, our                                       - 10 -       _________________________________________________________________    [45]Table of <font color="blue">Contents       </font>failure to <font color="blue">comply with</font> these <font color="blue">regulations</font> could subject us and our clients to     <font color="blue">allegations</font>  of  <font color="blue">filing false</font> claims to the <font color="blue">government</font>al <font color="blue">reimbursement</font>     programs,  <font color="blue">which could</font> subject us to substantial <font color="blue">financial damages</font> and     <font color="blue">exclusion from</font> the <font color="blue">government</font>al <font color="blue">reimbursement</font> programs</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> licensure <font color="blue">requirement</font>s, fraud and <font color="blue">abuse laws</font>, or     other <font color="blue">applicable laws</font>, we may need to curtail <font color="blue">operations</font>, and we could be     subject to <font color="blue">significant</font> penalties</td>
    </tr>
    <tr>
      <td>While we <font color="blue">continually monitor</font> the effects of     <font color="blue">regulatory</font> activity on our <font color="blue">operations</font> and believe we currently have all     <font color="blue"><font color="blue">necessary</font> pharmacy licenses</font>, the failure to obtain or renew any required     <font color="blue">regulatory</font>  approvals or <font color="blue">licenses could</font> <font color="blue">adversely</font> affect the continued     operation of the business</td>
    </tr>
    <tr>
      <td>The long-term care <font color="blue">facilities</font> that contract for     our services are also subject to federal, state and local <font color="blue">regulations</font> and     are required to be licensed in the states in which they are located</td>
    </tr>
    <tr>
      <td>The     <font color="blue">failure by</font> these long-term care <font color="blue">facilities</font> to <font color="blue">comply with</font> these or future     <font color="blue">regulations</font> or to obtain or renew any required <font color="blue">licenses could</font> result in our     <font color="blue">inability</font>  to  provide <font color="blue">pharmacy services</font> to these <font color="blue">facilities</font> and their     residents</td>
    </tr>
    <tr>
      <td>We are also subject to federal and state laws that prohibit some     types of direct and <font color="blue">indirect payments between healthcare providers</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>laws, commonly known as the fraud and <font color="blue">abuse laws</font>, prohibit payments or any     other <font color="blue">remuneration intended</font> to induce or encourage the referral of items or     <font color="blue">services payable by</font> Medicare or Medicaid, including <font color="blue">prescription</font> drugs</td>
    </tr>
    <tr>
      <td>For     example, payment by <font color="blue">pharmaceutical</font> <font color="blue">manufacturers</font> of access or performance     rebates to <font color="blue">institutional</font> pharmacies that are designed to prefer, protect, or     maintain  that  manufacturer’s product selection by the pharmacy or to     increase the volume of that manufacturer’s products that are <font color="blue">dispensed by</font>     the  <font color="blue">pharmacy under</font> its formulary are <font color="blue">currently under scrutiny</font> and may     violate the fraud and <font color="blue">abuse laws</font></td>
    </tr>
    <tr>
      <td><font color="blue">Violation </font>of these laws can result in loss     of licensure, civil and <font color="blue">criminal penalties</font>, and <font color="blue">exclusion from</font> the Medicaid,     Medicare and other federal and state <font color="blue">healthcare programs</font></td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">comply with</font> federal or state <font color="blue"><font color="blue">health care</font> privacy standards</font>     could subject us to civil and <font color="blue">criminal liability</font></td>
    </tr>
    <tr>
      <td>The Health Insurance Portability and Accountability Act of 1996     (“HIPAA”) requires us to <font color="blue">comply with</font> the electronic <font color="blue">transaction</font>, privacy and     <font color="blue">security standards</font> relating to the <font color="blue">health care</font> information of <font color="blue">individuals</font>     who receive drugs and <font color="blue"><font color="blue">pharmaceutical</font>s</font> through our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Although we     have taken and intend to continue to take all steps <font color="blue">necessary</font> to ensure that     we <font color="blue">comply with</font> all HIPAA standards, if we fail to <font color="blue">comply with</font> the <font color="blue">HIPAA     </font><font color="blue">regulations</font>, we could suffer <font color="blue">significant</font> civil and <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>We     may also become subject to various state <font color="blue">legislative</font> and <font color="blue">regulatory</font> privacy     <font color="blue">initiatives</font> that <font color="blue">will restrict</font> the use of <font color="blue">private medical records</font>, and, if     these <font color="blue">regulations</font> are implemented, we may incur <font color="blue">additional</font> expense and may     be required to change certain of our business practices</td>
    </tr>
    <tr>
      <td>We  are  also  subject to other state and <font color="blue">federal laws</font> that govern the     <font color="blue">distribution</font> of <font color="blue"><font color="blue">pharmaceutical</font>s</font>, the <font color="blue">enforcement</font> of <font color="blue">which could</font> have a     material and adverse effect on our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We are also subject to the risk of changes in various local,     state, federal and <font color="blue">international laws</font> relating to <font color="blue"><font color="blue">pharmaceutical</font>s</font>, which     include the operating and <font color="blue">security standards</font> of the <font color="blue">United States </font>Drug     Enforcement Administration, the <font color="blue">United States </font>Food and Drug Administration,     various state boards of pharmacy and <font color="blue">comparable agencies</font></td>
    </tr>
    <tr>
      <td>These changes may     affect   our   <font color="blue">operations</font>,   including  <font color="blue">distribution</font>  of  <font color="blue">prescription</font>     <font color="blue"><font color="blue">pharmaceutical</font>s</font> (including certain controlled substances), operation of     pharmacies and packaging of <font color="blue"><font color="blue">pharmaceutical</font>s</font></td>
    </tr>
    <tr>
      <td>A review of our business by     <font color="blue">regulatory</font> authorities may result in <font color="blue"><font color="blue">determination</font>s</font> that could <font color="blue">adversely</font>     affect the <font color="blue">operations</font> of the business</td>
    </tr>
    <tr>
      <td>We are also subject to cost <font color="blue">controls imposed by</font> non-<font color="blue">government</font> <font color="blue">reimbursement</font>     <font color="blue">program payors</font> and pricing changes from our suppliers that could have a     material and adverse effect on our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Cost <font color="blue">controls imposed by</font> other third-party payors, such as managed     care companies and insurance companies, in an attempt to <font color="blue">exercise control</font>     over  increasing  health  care  costs  and  changes  in <font color="blue">pharmaceutical</font>     <font color="blue">manufacturers</font>’ pricing or <font color="blue">distribution</font> policies could also have a material     and  adverse effect on our <font color="blue">profitability</font> by <font color="blue">substantially</font> reducing our     revenues</td>
    </tr>
    <tr>
      <td>There are <font color="blue">few barriers</font> to entry in the <font color="blue"><font color="blue">institutional</font> pharmacy</font> market, and we     may experience <font color="blue">unforeseen competition</font> in our markets</td>
    </tr>
    <tr>
      <td>There are relatively <font color="blue">few barriers</font> to entry in the <font color="blue">local markets</font>     that we serve, and we <font color="blue">may encounter</font> substantial <font color="blue">competition from new local</font>     market entrants as well as increasing competition from pharmacies operating                                       - 11 -       _________________________________________________________________    [46]Table of <font color="blue">Contents       </font>outside  the <font color="blue">United States </font><font color="blue">which ship drugs</font> to US <font color="blue">residents over</font> the     Internet and through other <font color="blue">distribution</font> channels</td>
    </tr>
    <tr>
      <td>This <font color="blue">competition could</font>     have a material and adverse effect on our business</td>
    </tr>
    <tr>
      <td>Future sales of <font color="blue">common stock</font> could depress the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">previously</font> announced that we are attempting to raise     <font color="blue">additional</font> capital</td>
    </tr>
    <tr>
      <td>The planned <font color="blue">financings may</font> include, but not be limited     to,  a  <font color="blue">combination</font>  of privately placed <font color="blue">common stock</font>, senior debt and     <font color="blue">subordinated debt</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">amounts may vary depending upon</font> the structure of each     financing instrument</td>
    </tr>
    <tr>
      <td>Sales of <font color="blue">significant</font> amounts of <font color="blue">common stock</font> in the     <font color="blue">public market</font>, or the <font color="blue">perception</font> that <font color="blue">sales will</font> occur, could <font color="blue">materially</font>     depress the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We expect that any common     stock sold in any of this <font color="blue">private financing will</font> be registered for resale     under the <font color="blue">Securities Act </font>within 120 days following the closing of such     offering and thus would be <font color="blue">freely tradable</font></td>
    </tr>
    <tr>
      <td>We also have <font color="blue">outstanding three series</font> of convertible notes, which,     as of <font color="blue">December </font>31, 2005 are <font color="blue">convertible into</font> an aggregate of 2cmam927cmam483     shares of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have registered these shares for resale so that,     upon conversion, such shares will be <font color="blue">freely tradable</font></td>
    </tr>
    <tr>
      <td>Further, we have     <font color="blue">outstanding warrants</font> to purchase an aggregate of 748cmam130 shares of common     stock</td>
    </tr>
    <tr>
      <td>The shares of <font color="blue">common stock</font> underlying such warrants are subject to     <font color="blue">registration rights</font> or are otherwise currently <font color="blue">freely tradable</font></td>
    </tr>
    <tr>
      <td>In addition, as of <font color="blue">December </font>31, 2005 we have an aggregate of     2cmam222cmam180 shares of <font color="blue">common stock</font> issuable in our <font color="blue">two stock option</font> plans upon     the  exercise of <font color="blue"><font color="blue">stock options</font> currently outstanding</font></td>
    </tr>
    <tr>
      <td>Those shares, if     issued, will be eligible for <font color="blue">immediate resale</font> in the market (other than     1cmam427cmam614  <font color="blue">shares underlying exercisable options</font> held by our executive     officers and <font color="blue">directors</font>)</td>
    </tr>
    <tr>
      <td>Finally, we have announced our intention to commence an exchange     offer for all or a portion of our <font color="blue">outstanding <font color="blue">trust preferred securities</font></font>, in     which  <font color="blue">holders will</font> be offered the <font color="blue">opportunity</font> to exchange their trust     preferred  securities  for shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have not yet     determined the terms of the <font color="blue">exchange offer</font>, including the <font color="blue">exchange ratio</font></td>
    </tr>
    <tr>
      <td>As     a result, while the <font color="blue">exchange offer</font> will likely result in the issuance of a     <font color="blue">significant</font> number of <font color="blue">additional</font> shares of our <font color="blue">common stock</font>, we cannot     <font color="blue">presently quantify how</font> many <font color="blue">new shares will</font> be issued</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> is volatile</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> historically has experienced     and <font color="blue">may continue</font> to experience <font color="blue">significant</font> <font color="blue">volatility</font></td>
    </tr>
    <tr>
      <td>This <font color="blue"><font color="blue">volatility</font> may</font>     or may not be related to our operating performance</td>
    </tr>
    <tr>
      <td>Some of this <font color="blue">volatility</font>     may be related to our recent shift to operating solely in the healthcare     business  and  as a much <font color="blue">smaller company</font>, and may reflect the market’s     <font color="blue">difficult</font>y in valuing our business until we establish a longer operating     history</td>
    </tr>
    <tr>
      <td>In addition, announcements of our quarterly operating results,     changes in recommendations by financial analysts, fluctuations in the stock     price and operating results of our <font color="blue">competitors</font> and similar <font color="blue">events could</font>     cause the <font color="blue">market price</font> of our <font color="blue">common stock</font> to fluctuate <font color="blue">substantially</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that our <font color="blue">securities will continue</font> to meet the listing     and <font color="blue">maintenance criteria</font> for the <font color="blue">Nasdaq Stock Market</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">common stock</font> is <font color="blue">currently traded on</font> the Nasdaq National     Market</td>
    </tr>
    <tr>
      <td><font color="blue">Continued  </font>inclusion  on the <font color="blue">Nasdaq National Market </font>currently     requires, among other things, a minimum stockholder’s equity of dlra10 million</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, our stockholder’s equity was dlra4dtta9 million</td>
    </tr>
    <tr>
      <td>In     addition, Nasdaq requires that the <font color="blue">minimum bid price</font> for <font color="blue">listed companies</font>     exceed dlra1dtta00 per share</td>
    </tr>
    <tr>
      <td>Recently, our shares of <font color="blue">common stock</font> have traded     <font color="blue">consistently under</font> the dlra1dtta00 <font color="blue">minimum bid price</font></td>
    </tr>
    <tr>
      <td>In a letter dated April 3,     2006, we were <font color="blue">notified by</font> Nasdaq that our stock price traded under dlra1dtta00 per     share for the last 30 consecutive business days</td>
    </tr>
    <tr>
      <td>The <font color="blue">letter advised</font> that we     have until October 2, 2006 to regain <font color="blue">compliance with</font> this <font color="blue">minimum bid price</font>     <font color="blue">requirement</font></td>
    </tr>
    <tr>
      <td>We intend to monitor the bid price of our <font color="blue">common stock</font> between     now and October 2, 2006, and consider <font color="blue">various options available</font> to us in the     event our <font color="blue">common stock</font> does not trade at a level that is likely to regain     compliance</td>
    </tr>
    <tr>
      <td>If we fail to maintain the minimum threshold <font color="blue">requirement</font>s to     maintain our <font color="blue">inclusion on</font> the Nasdaq National Market, our <font color="blue">securities would</font>     lose their listing <font color="blue">which could</font> further <font color="blue">negatively</font> impact the price and     marketability of our shares, and <font color="blue">trading would</font> be conducted, if we qualify,     on the <font color="blue">Nasdaq Capital Market </font>or if we do not qualify for such market, then     in the over-the-counter market known as the NASD OTC Electronic Bulletin     Board</td>
    </tr>
    <tr>
      <td>As a result, an investor may find it more <font color="blue">difficult</font> to dispose of, or     to obtain accurate <font color="blue">quotations as</font> to the <font color="blue">market value</font> of our securities</td>
    </tr>
    <tr>
      <td>- 12 -       _________________________________________________________________    [47]Table of <font color="blue">Contents       </font>          In addition, the SEC has adopted <font color="blue">regulations</font> which generally     define “<font color="blue">penny stock</font>” to be any <font color="blue">equity security</font> that has a <font color="blue">market price</font> less     than dlra5dtta00 per share or an <font color="blue">exercise price</font> of less than dlra5dtta00 per share     subject to <font color="blue">certain exceptions</font></td>
    </tr>
    <tr>
      <td>If our securities are <font color="blue">removed from listing on</font>     the Nasdaq Market, and are traded at a price below dlra5dtta00, they may become     subject to rules that impose <font color="blue">additional</font> sales practice <font color="blue">requirement</font>s on     broker-dealers who sell such securities to persons other than established     customers and <font color="blue">institutional</font> <font color="blue">accredited</font> investors</td>
    </tr>
    <tr>
      <td>For <font color="blue"><font color="blue">transaction</font>s</font> covered     by  these  rules,  the  broker-dealer  must make a <font color="blue">special suitability</font>     <font color="blue">determination</font> for the purchase of the securities and have received the     purchaser’s  <font color="blue">written consent</font> to the <font color="blue"><font color="blue">transaction</font> prior</font> to the purchase</td>
    </tr>
    <tr>
      <td>Additionally, for any <font color="blue">transaction</font> involving a <font color="blue">penny stock</font>, unless exempt,     the rules require the delivery, prior to the <font color="blue">transaction</font>, of a <font color="blue">disclosure</font>     schedule prepared by the SEC relating to the <font color="blue"><font color="blue">penny stock</font> market</font> and the     risks of investing in our securities</td>
    </tr>
    <tr>
      <td>The broker-dealer also must disclose     the  <font color="blue">commissions</font>  payable to both the broker-dealer and the registered     <font color="blue">representative</font>,  current  quotations  for  the securities, and, if the     broker-dealer is the sole market-maker, the broker-dealer must disclose this     fact and the broker-dealer’s presumed <font color="blue">control over</font> the market</td>
    </tr>
    <tr>
      <td>Finally,     <font color="blue">monthly statements must</font> be sent disclosing <font color="blue">recent price</font> information for the     <font color="blue">penny stock</font> held in the account and information on the limited market in     <font color="blue">penny stock</font>s</td>
    </tr>
    <tr>
      <td>Consequently, the “<font color="blue">penny stock</font>” rules may restrict the ability     of broker-dealers to sell our securities and may affect your ability to sell     our securities in the <font color="blue">secondary market</font></td>
    </tr>
    <tr>
      <td>You may experience <font color="blue">dilution as</font> a result of <font color="blue">future issuances</font> of shares of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had 9cmam095cmam208 shares of <font color="blue">common stock</font>     outstanding</td>
    </tr>
    <tr>
      <td>Additionally, as of <font color="blue">December </font>31, 2005, we had <font color="blue">stock options</font>,     warrants and convertible securities outstanding that were convertible or     <font color="blue">exercisable into up</font> to 5cmam897cmam793 shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Furthermore, in     <font color="blue">connection</font> with our <font color="blue"><font color="blue">acquisition</font> strategy</font>, we may issue shares of our common     stock as <font color="blue">consideration</font> in certain future <font color="blue">acquisition</font> <font color="blue"><font color="blue">transaction</font>s</font></td>
    </tr>
    <tr>
      <td>We are     <font color="blue">also likely</font> to issue a <font color="blue">significant</font> number of shares in the planned exchange     offer for our <font color="blue">trust preferred securities</font></td>
    </tr>
    <tr>
      <td>We may also issue <font color="blue">additional</font>     <font color="blue">shares as warrants</font> to purchase <font color="blue">additional</font> shares in the <font color="blue">future through</font>     <font color="blue">various financing</font> or restructuring <font color="blue"><font color="blue">transaction</font>s</font>, although, there are no firm     plans  for  such <font color="blue"><font color="blue">transaction</font>s</font> at this time</td>
    </tr>
    <tr>
      <td>In the event that we issue     <font color="blue">additional</font> <font color="blue">common stock</font> in the future, our share<font color="blue">holders will</font> experience     dilution the significance of <font color="blue">which will depend on</font> the number of shares     issued</td>
    </tr>
  </tbody>
</table>